The Varied Roles of Nuclear Argonaute-Small RNA Complexes and Avenues for Therapy

Jason P Ross1 and Zena Kassir1,2

Argonautes are highly conserved proteins found in almost all eukaryotes and some bacteria and archaea. In humans, there are eight argonaute proteins evenly distributed across two clades, the Ago clade (AGO1-4) and the Piwi clade (PIWIL1-4). The function of Ago proteins is best characterized by their role in RNA interference (RNAi) and cytoplasmic post-transcriptional gene silencing (PTGS) – which involves the loading of siRNA or miRNA into argonaute to direct silencing of genes at the posttranscriptional or translational level. However, nuclear-localized, as opposed to cytoplasmic, argonaute-small RNA complexes may also orchestrate the mechanistically very different process of transcriptional gene silencing, which results in prevention of transcription from a gene locus by the formation of silent chromatin domains. More recently, the role of argonaute in other aspects of epigenetic regulation of chromatin, alternative splicing and DNA repair is emerging. This review focuses on the activity of nuclear-localized short RNA-argonaute complexes in a mammalian setting and discusses recent in vivo studies employing nuclear-directed sRNA for therapeutic interventions. These studies heed the potential development of RNA-based drugs which induce epigenetic changes in the cell.

Molecular Therapy—Nucleic Acids (2014) 3, e203; doi:10.1038/mtna.2014.54; published online 14 October 2014

Subject Category: non-coding RNA special issue

Introduction

The argonautes are a family of highly evolutionarily conserved proteins that bind small-RNAs (sRNA) and have essential roles in the RNA interference and microRNA pathways (reviewed in ref. 1). Argonaute proteins are broadly classified into two main evolutionary clades; the Ago clade binds small ~20–30 nt non-coding RNAs which include microRNAs (miRNAs) and small interfering RNAs (siRNAs), while the Piwi clade Ago binds P-element induced wimpy testis (PIWI)-interacting RNAs (piRNAs), Wago, a third clade, is particular to nematode worms.2 Argonautes are characterized by a Piwi-Argonaute-Zwille (PAZ) domain and a PIWI domain. This PAZ domain functions by binding specifically to the 3’ end of single-stranded RNA and is also found in the Dicer enzyme. The PIWI pathway is thought to be confined to regulating RNA expression in germ cells (reviewed in ref. 4). The Ago pathway is ubiquitously expressed and in mammals is composed of four enzymes, Ago1, Ago2, Ago3, and Ago4 which are all capable of loading small RNA. This review will focus on the Ago pathway.

Ago2 is well studied as it is the “catalytic engine” that drives mRNA cleavage at miRNA target sites5,6 and is required for embryonic development.5,7 Ago2 is best characterized in its role in post-transcriptional gene silencing (PTGS). PTGS is a cytoplasmic process which involves the loading of the guide strand of the ~20–24 nt sRNA species, siRNA or miRNA, into the Ago2-containing RNA induced silencing complex (RISC), which can then recognize a complementary miRNA target and bind to inhibit translation or destabilize through the Ago2 endonuclease activity (reviewed in ref. 8). While PTGS was first characterized as a genome/viral defence, there are many small endogenous miRNAs, in particular, Ago2 and endo-siRNA in mammalian embryonic stem cells.8 siRNA are generated by Dicer RNase cutting of long dsRNA, such as that produced in virus replication, while miRNA are processed from nuclear hairpin dsRNA into short hairpin pre-miRNA by DGC8 and Drosha, an RNase III–type endonuclease, with subsequent transport to the cytoplasm and further cleavage by Dicer (reviewed in ref. 10) (Figure 1a). Except, in the case of miR-451, as its pre-miRNA is processed directly by Ago2 instead of Dicer.11,12 The loading of the sRNA guide strand into Ago requires the Dicer and TRBP containing RISC, with subsequent activation requiring the C3PO complex for efficient passenger strand removal.13,14 In humans, it is thought C3PO may be the sole loader and activator of Ago2.15

While Ago2 is well studied, much less is known about the function of the other argonautes. Ago1 is 80% identical to Ago2 but lacks a key catalytic residue and cannot cleave RNA efficiently. It is associated with the loading of specific sRNAs derived from the Epstein–Barr virus16 and Ago1 and/or Ago3 is required for optimal resistance to influenza-A in mice.17 Little is known about the function of Ago1 except that its overexpression slows neuroblastoma growth.18 Ago3, like Ago2, contains the catalytic residues essential for cleavage and is required to induce human embryonic stem cell proliferation arrest through binding of sRNA generated from transcribed Alu repeats and subsequent PTGS of critical stem cell mRNAs.19 Ago4 has been reported to localise to mouse spermatocyte nuclei during meiotic prophase and regulate meiotic entry.20

Sequencing or microarray analysis of endogenous sRNA bound to human Ago1, Ago2 and Ago3 shows that the great majority is miRNA, which has been loaded with no particular strand bias towards the pre-miRNA 3p (antisense) or 5p (sense) strand.21–23 However, those miRNA preferentially

1CSIRO Food and Nutrition Flagship, Sydney, New South Wales, Australia; 2Garvan Institute of Medical Research, Sydney, New South Wales, Australia Correspondence: Jason P Ross, Research Scientist, CSIRO Food and Nutrition Flagship, PO Box 52, North Ryde, Sydney, New South Wales 1670, Australia. E-mail: Jason.ross@csiro.au

Keywords: Ago; argonaute; microRNA; miRNA; nuclear; RNAs; siRNA; TGS; therapy

Received 30 June 2014; accepted 22 August 2014; published online 14 October 2014. doi:10.1038/mtna.2014.54
Figure 1 The role of argonaute in transcriptional gene silencing (TGS) and activation (RNAa). (a) The dicer-generated small RNA (sRNA) species which are loaded into argonaute (gray box) can be derived from shRNA expressed from plasmids or viral vectors transfected into the cell, or from endogenous processes, such as miRNA biogenesis or dsRNA resulting from bivalent transcription. Alternatively, siRNA directly transfected into the cell may be loaded. The sRNA species have a single “guide” strand loaded into argonaute while the other “passenger” strand is degraded. (b) Loaded Ago1 (Ago1+sRNA) may enter the nucleus and together with a nuclear RISC (nucRISC) and in association with active RNAPII and sense transcripts, initiate chromatin remodelling and transcriptional gene silencing (TGS) by such enzymes as histone 3 lysine 9 methyltransferases (H3K9 HMTase). The loaded Ago2 (Ago2+sRNA) is catalytically active and may direct the silencing of mature mRNA in the cytoplasm via the post-transcriptional gene silencing (PTGS) pathway, or it may be migrate to the periphery of the nucleus and (perhaps in association with a nucRISC), degrade primarily antisense transcripts. This process is associated with remodeling to active chromatin by histone 3 lysine 4 histone methyltransferases (H3K4 HMTase) and subsequent transcriptional gene activation (RNAa). There is also evidence nuclear Ago2 is associated with TGS.
loaded into Ago1 or Ago2 had distinct antisense and sense bias, respectively. Other endogenous sRNA are also bound to Ago, as well as sRNA from intronic and exonic coding gene regions and promoter regions of coding genes. Many of these sRNA species were longer than the 21 nt canonical length, in particular promoter-derived RNAs were mostly of 21–24 nucleotides in length and mostly associated with Ago1 and Ago3. The differential loading between Ago1 and Ago2 might be due, in part, to editing of the 3′-end, with miRNA terminating in 3′ adenine and uracil preferentially loaded into Ago1 and Ago2, respectively.25 This differs from piRNA loaded into PIWI-clade Ago, as these are 2′-O-methylated at the 3′ termini and often include uracil at the 5′ end.26–27 Recent findings show that in Ago1-4 knockout mouse embryonic stem cells, expression of inducible Ago2 confers miRNA stability.28 Interestingly, this same work unveiled a new class of Ago/Dicer-dependent miRNAs which arise from the transcription start site (TSS-miRNA) of RNAPII protein-coding gene promoters.

Function in the Nucleus

Over the last decade or so, Ago has been recognized as having a role in the nucleus. RNA-induced silencing complexes (RISCs) containing Ago1 and Ago2 are present in both the cytosolic and nuclear fractions of human cells29–31 and Ago1 and ago2 are known to associate with promoter DNA.32 Argonaute–RNA complexes can regulate nuclear events such as transcriptional silencing and activation as well as alternative splicing and DNA repair.34–36 Nuclear Ago1 directly interacts with RNA polymerase II (RNAPII)30,37,38 and binds to the promoters of actively transcribed genes.30,38 There are two contrary reports that describe human nuclear Ago2 as part of a multiprotein complex together with Dicer, TRBP and TRNC6A/GW182,39 or conversely in solitary form.40 However, both of these studies agree that Ago2 is loaded in the cytoplasm and imported into the nucleus (Figure 1b).

Using immunofluorescence microscopy, two groups have shown that tagged Ago1 and Ago2 have different nuclear distributions. Ago1 is scattered throughout the nuclear interior, whereas Ago2 co-localizes with siRNA primarily in the inner nuclear envelope.40,41 ChIP-seq data shows that Ago1 is associated with thousands of chromosomal loci throughout the genome, but in particular with the promoters of actively transcribed genes and distributed in highly punctate peaks mostly overlapping with histone 3 lysine 4 tri-methylation (H3K4me3).40 In the same study, there was no evidence to suggest Ago2 interacts with chromatin. Sequencing of sRNA bound to argonaute in whole-cell lysate from mouse T cells, shows that ~0.02% of reads map to promoter regions, with twofold more bound to Ago1 and Ago3, than to Ago2. Around 0.2% of Ago1 tags mapped to coding regions, which was six- and twofold more than Ago2 and Ago3, respectively. Over 80% of tags mapping in the antisense direction were bound to Ago1, while for sense tags, the split was closer across Ago proteins.22

Dicer also has a nuclear localization signal, in the dsRNA binding domain42 and there is clear evidence it is nuclear-imported. Nuclear Dicer has been variously reported as located in the nuclear periphery in association with NUP153, a component of the nuclear pore complex,43 or spread throughout the nucleoplasm with a punctate distribution.44 Nuclear Dicer is associated with RNAPII at actively transcribed genes and is required for Ago1-mediated TGS.44 Furthermore, nuclear Dicer is catalytically active and will cleave target RNA,25,39,44,45 with knockdown resulting in accumulation of endogenous double-stranded RNA (dsRNA), induction of the interferon-response pathway and cell death.44 Dicer is known to be important for the epigenetic regulation of the cell as its activity is required for the correct formation of heterochromatin structure in mammalian cells.46

Collectively, evidence suggests nuclear Ago1 binds mostly antisense sRNA and is distributed throughout the nucleus at promoters of active genes in association with RNAPII and Dicer, while nuclear Ago2 complexes are at the nuclear periphery and contain both sense and antisense sRNA.

Exogenous Small RNA Transcriptional Silencing and Activation

RNA-directed transcriptional gene silencing (TGS) is an important means of regulation, evident by the conservation of mechanism from yeast to plants to higher mammals (reviewed in ref. 47). The phenomenon of mammalian TGS was first reported by Morris et al. in 2004.48 They described transcriptional silencing of both endogenous and integrated proviral elongation factor 1-alpha 1 (EEF1A1) by delivery of a siRNA targeting the promoter region. This study was closely followed by those from several other groups also reporting TGS driven by promoter-directed siRNA targeting the HIV-1 viral LTR,49 CDH1,50 RASSF1,51 PGR, MVP, both AR and PTGS2 (ref. 52) and NOS3.53 The phenomenon has continued to be observed and clarified (Table 1).

The counter-phenomenon of mammalian sRNA-induced transcriptional gene activation (RNAa) was reported in 2006 by Li et al.54 who observed that transfecting siRNA complementary to the promoter regions of CDKN1A, CDH1, and VEGFA resulted in increased transcription of the respective gene. Unlike the early TGS studies, their promoter-directed dsRNA designs avoided promoter CpG-rich regions. These observations were soon supported by work from two other groups that reported RNAa of the HIV-1 viral LTR and PGR,54 respectively. RNAa resulting from a single transfection could be observed for between 9 and 13 days.73,75 Paradoxically, Janowski et al. showed that 21-mer ds siRNA designed against the progesterone receptor (PGR) as little as a few nucleotides apart could profoundly affect the activation potential and in some cases, cause TGS instead of RNAa.76 Subsequently, there are many more reports of small-RNA directed RNAa, including by groups also demonstrating TGS (Table 2).

Results showing suppression or activation of transcription by promoter-directed siRNA need to be interpreted with some caution. It is possible that alteration of observed transcriptional levels attributed to RNAa or TGS may in fact be the result of sequence-specific off-target effects. These off-target effects have been reported for siRNA designed against the VEGFA promoter50 and the HIV-1 LTR promoter.74
Requirement for Argonaute in Nuclear Processes

Knockdowns of argonaute protein have shown it is required for small-RNA induced TGS or RNAa (Tables 1 and 2). Some controversy exists about whether Ago1 or Ago2 is the main argonaute recruited to enact TGS. The first studies reported Ago1 as the key argonaute driving TGS, while some latter studies show evidence that only knockdown of Ago2 resulted in abrogation of TGS, with knockdown of Ago1, Ago3, or Ago4 not overly reducing the effect. In an early study, the Corey group reported that both Ago1 and Ago2 were required for TGS, however in later work they rationalized that off-target knockdowns may explain their earlier results. In the case of RNAa, fewer studies have examined the requirement for argonaute; however, there is no disagreement; all suggest that only Ago2 is required (Figure 2).

| Table 1 List of transcriptional gene silencing (TGS) studies |
|-------------------------------------------------------------|
| Study | Gene symbol | Cell line | Effector name | Effector type | Transfection | Location (wrt TSS) | Year | Citations | Reference |
|-------|-------------|-----------|---------------|---------------|--------------|-----------------|------|------------|-----------|
| 1     | CCR5/RASSF1 | HEK293T   | R61           | ds siRNA      | MPG          | NS              | 2006 | 247        | 37        |
| 2     | CDH1        | HCT-116/MCF-7 | dsCDH1-1, 2  | ds siRNA      | Lipid        | NS              | 2005 | 193        | 50        |
| 3     | CDKN1A      | MCF-7     | Bx3x2409      | ds siRNA      | Lipid        | NS              | 2008 | 133        | 54        |
| 4     | CDKN2A      | HEK293T   | p16siRNA      | U6shRNA-cassette | Calcium phosphate | NS              | 2007 | 16         | 55        |
| 5     | EEF1A1      | 293FT     | EF52          | ds siRNA      | MPG           | −106            | 2004 | 570        | 48        |
| 6     | EEF1A1      | Many      | EF52          | ds siRNA      | Lipid         | −106            | 2007 | 160        | 56        |
| 7     | EEF1A1/HIV-1 | HEK293T   | EF52/siRNA-247| ds or ss siRNA | MPG           | −125/viral 247  | 2006 | 151        | 57        |
| 8     | HIV-1 (Viral LTR) | T2Z-bl   | 247as, 362as | antisense-RNA | Lipid         | NS              | 2009 | 27         | 58        |
| 9     | HIV-1 (Viral LTR) | MAGIC-5   | HIV-prom-A    | siRNA         | Lipid         | −100            | 2005 | 74         | 49        |
| 10    | HIV-1 (Viral LTR) | MAGIC-5   | HIV-prom-A    | ds siRNA      | Electroporation | −100            | 2008 | 46         | 59        |
| 11    | HIV-1 (Viral LTR) | Molt-4     | shKB          | U6shRNA       | Retrovirus    | NS              | 2009 | 25         | 60        |
| 12    | HPA         | PC3/EJ/SGC-7901 | siH3         | siRNA, shRNA | Lipid         | −9              | 2012 | 15         | 61        |
| 13    | MSTN        | Mouse C2C12 | siMstn-P2    | siRNA         | Lipid         | −153            | 2012 | 3          | 62        |
| 14    | MYC         | PC3, DU145, LNCaP | mcy13       | ds siRNA      | Lipid         | −13             | 2009 | 58         | 63        |
| 15    | NOS3        | HAEC      | "microRNA"   | 27mer-siRNA   | Lipid         | Intron-4        | 2005 | 74         | 53        |
| 16    | PGR         | T47D      | PR9           | ds siRNA      | Lipid         | −9              | 2008 | 121        | 64        |
| 17    | PGR         | T47D      | PR9           | ds siRNA      | Lipid         | −9              | 2010 | 41         | 29        |
| 18    | PGR         | T47D      | PR13580       | ds siRNA      | Lipid         | +13580          | 2010 | 34         | 65        |
| 19    | PGR, AR, HTT | T47D/MCF-7 | Many         | ds siRNA      | Lipid         | Many            | 2006 | 176        | 33        |
| 20    | PGR, IGSF1  | T47D/MCF-7 | miR-423-5p   | ds miRNA      | Lipid         | −59             | 2011 | 41         | 66        |
| 21    | PGR, MVP, AR, PTGS2 | T47D   | Many         | ds siRNA      | Lipid         | Many            | 2005 | 98         | 52        |
| 22    | PLAU        | PC3/DU145 | siuPA pool of 4 | ds siRNA    | Lipid         | −213, −131, −111, −50 | 2007 | 50         | 67        |
| 23    | POLR3D      | HEK293    | miR-320       | ds miRNA      | Lipid         | −132            | 2008 | 254        | 68        |
| 24    | RASSF1      | HeLa      | ShPr21        | U6shRNA       | Vector         | −28             | 2005 | 94         | 51        |
| 25    | SIV (Viral LTR) | MAGIC-5, CEMx174 | Many       | ds siRNA      | Lipid         | NS              | 2008 | 20         | 69        |
| 26    | TGFβRlII    | Rat SBC10 | siRNA-p-412   | U6shRNA       | Vector         | −412            | 2007 | 23         | 70        |
| 27    | UBC         | HEK293T   | UBC167        | ds siRNA      | Lipid         | −167            | 2009 | 86         | 71        |
| 28    | VEGFA       | C166      | LV-856        | U6shRNA       | Retrovirus    | NS              | 2009 | 43         | 72        |

4′-most location with respect to the transcriptional start site of the target. A negative number implies an upstream location and “NS” denotes the location was not stated. *Citations according to Web of Science (July 2014).

Association with Transcription, Epigenetic Regulation, and RISC Subunits

Early models speculated that siRNA might directly base-pair with DNA and recruit DNA methyltransferase (DNMT), but work by ourselves and others has shown that DNMTs cannot methylate DNA:RNA hybrid structures and that instead, Ago-loaded nuclear siRNA binds to nascently transcribed RNA. There are a number of reports that TGS requires active transcription by RNAPII and expression of sense-transcript miRNA through the gene promoter. However, other data shows that Ago1 and Ago2 bind to antisense transcripts during TGS. Interestingly, transfection of only the siRNA anti-sense strand is sufficient to silence the EEF1A1 gene. Matsui et al. report Ago2-dependent transcriptional gene activation of PTGS2 by the endogenous miRNA, miR-589. As only one strand of miR-589 is complementary...
to the promoter RNA, they posit that the sense strand is the only potential partner for gene activation. In agreement, microarray data shows that in MCF7 cells, miRNA with biased Ago2 association are predominantly derived from sense strands of the corresponding pre-miRNA, while the majority of Ago1-associated miRNAs originate from the anti-sense strand.23

In accord with expectation, there is clear evidence that, after TGS, less RNAPII is found at promoters, 29,33,53,61–66 while after RNAa, there is enrichment for RNAPII. 29,38,65,76,85 Most studies that have examined chromatin regulation found promoters after TGS to be enriched for histones with silencing marks and those after RNAa with active marks (Figure 2). In particular, TGS is associated with enrichment for the repressive histone 3, lysine 9 di- and tri-methylation (H3K9me2, H3K9me3) and lysine 27 tri-methylation (H3K27me3) marks, with loss of the active histone 3 lysine 9 acetylation (H3K9Ac), lysine 14 acetylation (H3K14Ac) marks and in some cases loss of the active H3K4me3 mark. For RNAa, histone regulation is reversed, with loss of repressive H3K9me2 and H3K27me3 marks and gain of the activating H3K4me2 and H3K4me3 marks. Intriguingly, like TGS, RNAa is associated with the loss of H3K9ac and H3K14ac marks. These marks are associated with active and bivalent promoters in mouse cells.82 Some TGS studies report an increase in DNA methylation at the targeted promoter (Figure 2). The de novo methyltransferase Dnmt3a is required to establish DNA methylation at the targeted region of the promoter and Dnmt1 is required for maintenance of that methylation.58,71

Knockdown experiments suggest a TGS requirement for the chromatin condensation-associated histone deacetylase HDAC, perhaps the H3K9 methyltransferase G9a, but not the polycomb-group H3K27 methyltransferase, EZH2. 58,71 However, in ChIP experiments from two TGS studies, EZH2 is enriched at target promoters.37,68 There is also a requirement in TGS for the RISC-loading complex subunit, TARBP2. 37 For RNAa, it has been reported that activation of the PTGS2 locus required the WD repeat-containing protein 5 (WDR5) and the argonaute-interacting, GW182. 89 Interestingly, the long intergenic ncRNA (lncRNA), HOTTIP, transcribed from the 5′-end of the HOXA locus, binds to WDR5 and in turn, mixed-lineage leukaemia (MLL) histone methyltransferase, which drives gene activation and H3K4 trimethylation (H3K4me3). This same histone mark is known to be enriched in RNAa (Table 2).72,75,89 This suggests transcriptional gene activation by short RNA and IncRNA may share a number of features in common.

### Table 2 List of transcriptional gene activation (RNAa) studies

| Study | Gene symbol | Cell line | Effector name | Effector type | Transfection | Location (wrt TSS) | Year | Citations | Reference |
|-------|-------------|-----------|---------------|---------------|---------------|-------------------|------|------------|-----------|
| 1     | CCNB1       | TRAMP C1  | miR-744, miR-1186 | ds miRNA    | Lipid, Retrovirus | −192/−699 | 2012 | 34 38     |           |
| 2     | CDH1        | PC3       | miR-373       | ds miRNA    | Lipid         | −645             | 2008 | 358 76    |           |
| 3     | CDH1        | MBA-453/MCF-7, in vivo | ds Ecad215 | ds siRNA    | Lipid         | −215             | 2010 | 12 77     |           |
| 4     | CDKN1A      | A549 and in vivo | dsP21-322 | ds siRNA    | Lipid         | −322             | 2010 | 18 78     |           |
| 5     | CDKN1A      | MCF-7    | p21-322       | ds siRNA    | Lipid, NS    | 2008             | 133 54 |         |           |
| 6     | CDKN1A      | T24/J82  | ds P21       | ds siRNA    | Lipid         | −322             | 2008 | 48 79     |           |
| 7     | CDKN1A      | A498     | dsP21-322     | ds siRNA    | Lipid         | −322             | 2009 | 18 80     |           |
| 8     | CDKN1A      | T24      | ds P21       | ds siRNA    | Lipid         | −322             | 2008 | 24 81     |           |
| 9     | CDKN1A      | S637     | ds Ecad215    | ds siRNA    | Lipid         | −215             | 2008 | 20 82     |           |
| 10    | CDKN1A      | PC3      | dsEcad215     | ds siRNA    | Lipid         | −215             | 2010 | 6 83      |           |
| 11    | CDKN1A, CD1, VEGFA | Many     | Many       | ds siRNA    | Lipid         | Many             | 2006 | 297 73    |           |
| 12    | HIV-1 (Viral LTR) | 1G5       | LTR-247as+7  | siRNA-cassette | Vector     | Viral 254       | 2007 | 21 74     |           |
| 13    | KLF4        | Many     | dsKLF4-496    | ds siRNA    | Lipid         | −496             | 2010 | 40 84     |           |
| 14    | LDLR        | HepG2    | LDLR-24, LDLR-28 | ds siRNA | Lipid         | −24/+28          | 2010 | 24 85     |           |
| 15    | Many        | Mammalian cell lines | Many       | ds siRNA    | Lipid         | NS                | 2010 | 49 86     |           |
| 16    | NANOG       | NCCIT    | ds Nanog-752  | ds siRNA    | Lipid         | −752             | 2012 | 9 87      |           |
| 17    | PAWR        | Many     | ds PAWR-435   | ds siRNA    | Lipid         | −435             | 2013 | 2 88      |           |
| 18    | PGR         | T47D/MCF-7 | PR11       | ds siRNA    | Lipid         | −11              | 2007 | 214 75 |           |
| 19    | PGR         | MCF-7    | PR11         | ds siRNA    | Lipid         | −11              | 2008 | 121 64    |           |
| 20    | PGR         | MCF-7    | PR11         | ds siRNA    | Lipid         | −11              | 2010 | 41 29     |           |
| 21    | PGR         | MCF-7    | PR13515      | ds siRNA    | Lipid         | +13515           | 2010 | 34 65     |           |
| 22    | PTGS2       | A549     | miR-549/RNA12 | ds miRNA/ siRNA | Lipid       | −57/+34          | 2013 | 5 89      |           |
| 23    | VEGFA       | C166     | LV-451       | U6shRNA     | Retrovirus    | NS                | 2009 | 43 72     |           |

*a5′-most location with respect to the transcriptional start site of the target. A negative number implies an upstream location and “NS” denotes the location was not stated. *Citations according to Web of Science (July 2014).
The initial observation of exogenous small-RNAs directing TGS suggested endogenous sRNAs such as miRNA or endo-siRNA may elicit the same phenomenon. The first examples of endogenous TGS and RNAa in mammals were of genes with predicted miRNA binding sites in their promoters; in particular the silencing of POLR3D by miR-320 (ref. 68) and PGR and IGSF1 by miR-423-5p (ref. 66) and the activation of CDKN1 transcription by miR-373, (ref. 76) PTGS2 transcription by miR-549 (ref. 89) and CCNB1 by miR-873 (ref. 38) (Tables 1 and 2). Huang et al. found Ago1 was enriched at the CCNB1 promoter, just proximal to the predicted miR-744-binding site, but did not find any enrichment for Ago2,38 Particular miRNA 5’ sequence elements may direct import of the mature miRNA back into the nucleus with this re-importation dependent on the association of Importin8 with Ago2.31,94 There is evidence that Ago2 is involved in control of chromatin structure at a genomic miRNA site,95,96 with Ago2 knockdown correlated with upregulation of expression of the miRNA-155 host gene primary transcript (miR-155HG), the overlapping antisense long noncoding RNA transcript and an increase in acetylation of histone 4 in the promoter region.95 Benhamed et al. describe senescence-associated transcriptional gene silencing (SA-TGS); during cellular senescence miRNA such as let-7 direct Ago2 to promoters of the tumor suppressor gene/transcription factors repressor complex (RB1/E2F) target genes (such as CDC2 and CDC48). These miRNA/Ago2 complexes block RNAPII engagement at target promoters and cooperate with E2F/RB1 complex to repress E2F-target promoters, resulting in increased H3K9me2 and H3K27me3 heterochromatin associated marks and a decrease in the active mark, H3K4me3.96 Ago2 accumulates in the nucleus of senescent cells, with Ago2 knockdown resulting in delayed senescence. This transcriptional repression of proliferation-promoting genes by SA-TGS may contribute to tumor suppression.

Figure 2 Required and enriched factors for transcriptional gene silencing and activation.
IncRNA
miRNA have an epigenetic TGS role either in cis as antisense targeting its own genomic location to silence adjacent gene transcription, or by associating with a methyltransferase such as EZH2, they may also function more broadly in TGS to target gene promoters in trans. IncRNA can also have both a cis and trans epigenetic role and can function in cis as antisense at the transcriptional level, regulating protein coding gene expression or in trans acting as scaffolds to mediate interactions that guide enzyme complexes to specific RNA or DNA target sites in order to exert their effect.

Despite IncRNA frequently being nuclear-localized, many have been found to interact with miRNA, suggestive of a role for nuclear Ago-miRNA complexes; however, direct evidence is lacking. Functionally, these miRNA-binding IncRNA, known as competing endogenous RNA (ceRNA), act like a “microRNA sponge” effectively reducing available miRNA. By antagonizing miRNAs, IncRNA are known to regulate several developmental processes. IncRNA interacting with miRNA can also result in histone modification and subsequent gene repression. For example, the IncRNA-miRNA complex of HULC and miR-372 recruits the histone modifying enzyme P300, a histone acetyltransferase and subsequently causes heterochromatin formation resulting in TGS.

Sense-antisense transcription frequently results in formation of dsRNA. It has long been known in Schizosaccharomyces pombe that dsRNAs target endogenous mRNAs for degradation via the Ago1 RNAi pathway (reviewed in ref. 107) and these interactions result in heterochromatin formation at specific DNA loci. Recently, antisense ncRNAs have been implicated in the silencing of tumor suppressor genes through epigenetic remodeling events in humans. miRNAs can recruit Ago2 to antisense IncRNA transcripts that overlap their target gene promoter. Younger et al. found miR-423-5p binds to RNA within the target progesterone receptor (PR) gene promoter, as well as ncRNA transcribed from the PR promoter, with TGS associated with recruitment of Ago2 to this ncRNA with subsequent decrease in promoter RNAPII occupancy and increase in the H3K9me2 mark. Other data shows nuclear Ago2-mediated regulation of the IncRNAs MALAT1 and the star-strand HOTAIR by miR-9 and miR-141, respectively. It appears that both MALAT1 and HOTAIR and most likely other IncRNAs may be functioning as a ceRNA and competing for mRNA target sites, mediated by Ago2. Evidence for this appears in recent global analyses of Ago-bound transcripts.

In the human genome, antisense transcription is widespread, which suggests a large potential for convergent transcription of overlapping transcripts to form endogenous dsRNA and to regulate the transcriptome. In S. pombe and mammals, convergent transcription induces TGS in trans. Antisense ncRNAs have been implicated in the silencing of tumor suppressor genes through epigenetic remodeling events in humans.

Argonate Association with Other Endogenous Processes
Alternative splicing
The introduction of exogenous duplex RNAs into the nucleus has been shown to redirect exon splicing of aberrant splice sites of the disease-associated SMN2 and dystrophin genes. The duplex RNAs recruited Ago2 to pre-mRNA transcripts and altered splicing without nuclear cleavage of the pre-mRNA. The first reported involvement of endogenous sRNA pathways in alternative-splicing was of the regulation of pre-miRNAs by MALAT. Subsequently, Ago1 and Ago2 have been identified in physical association with MALAT, chromatin modifiers and splicing factors. Using the CD44 gene as a model, the authors show that Dicer-dependent recruitment of Ago1 and Ago2 facilitated spliceosome recruitment and modulated RNAPII elongation rate thereby affecting alternative splicing. The recruitment of Ago1 and Ago2 to CD44 transcribed regions required the Dicer and histone modifying enzymes which resulted in increased H3K9 methylation on variant exons associated with heterochromatin and TGS.

Double strand break repair
The double strand break (DSB) repair role of Ago in plants is well known, however, this function has been recently found conserved in humans, with a reduction of DSB repair ability observed after knockdown of Dicer or Ago2. These DSB-induced small RNAs (diRNA) are produced from sense and antisense strands of DSB proximal sequence. In mammals, like in plants and Drosophila, diRNAs may function as guide molecules directing chromatin modifications which cause heterochromatin formation or the recruitment of protein complexes to DSB sites to facilitate repair. diRNA binding and catalytic activity of Ago2 are required for recruitment of the repair protein Rad51 to DSBs.

Model of Action
In the literature, there is conflicting information about the involvement of Ago1 and Ago2 in enacting transcriptional gene silencing and activation (see previous sections). More recent evidence suggests reconciliation into one central model is unnecessary. Instead, there is evidence for two discrete but overlapping pathways involved in TGS and RNAa (Figure 1b).

Generally, exogenous promoter-directed sRNA data shows that Ago1 is associated with TGS and transcription of sense promoter-associated RNA, while Ago2 is associated with both TGS and RNAa and antisense transcription (Figure 2). With regard to endogenous nuclear miRNA bound to Ago, the evidence suggests overlapping functionality of Ago1 and Ago2, but with some clear exceptions. Some miRNA species exhibit pre-miRNA antisense strand loading bias into Ago1 and the sense strand into Ago2. The interactions and location of argonuates within the nucleus reinforce the idea of discrete pathways of action. Ago1, but not Ago2, interacts directly with RNAPII and binds to the promoters of actively transcribed genes and only Ago1 has readily observable interactions with chromatin. Furthermore, Ago1 is dispersed throughout the nucleus, whereas Ago2 is primarily localized to the inner nuclear envelope. At the nuclear periphery are lamina associated domains (LADs), DNA which is known to be mostly maintained in a silent state with activation upon cellular differentiation (reviewed in ref. 116). The distribution of Ago2 in the vicinity of LADs is consistent with its involvement primarily in RNAa.
Ago2-induced RNAAs has some seemingly paradoxical observations, in particular, the observation that the PGR promoter-directed siRNAs PR9 and PR11 (Tables 1 and 2), designed only two nucleotides apart, may induce TGS in high PGR-expressing T47D cells and RNAAs in low PGR-expressing MCF-7 cells, respectively.29,33,64 RNAAs at the PGR locus is known to depend upon antisense transcription and involves the PR11-loaded Ago2.26,44

Perhaps these results can be explained by consideration of the findings by Morris et al.64 In their 2008 study, they provide evidence that sense transcription from the p21 (CDKN1A) locus is held in balance by transcription from overlapping antisense transcripts; i.e., Ago2-mediated PTGS of antisense transcription results in activation of p21 sense transcription, while—conversely—PTGS of p21 sense mRNA results in activation of p21 antisense transcription and the recruitment of Ago1 at the p21 promoter. They also show the presence of p21 antisense transcript and Ago1 are required for regulation of promoter-associated sense RNA and suppression of the p21 promoter. Their findings imply that apparent RNAAs is, in fact, the result of post-transcriptional repression of antisense RNA at bidirectionally transcribed loci. If instead PTGS is directed towards the sense RNA, this may result in increased promoter RNA transcription and reinforcement of silencing through recruitment of Ago1. This suggests that at bidirectional promoters, Ago1 and Ago2 may work in concert in the nucleus to reinforce cytoplasmic PTGS of gene loci. Indeed, genome-wide data shows that candidate antisense promoter-associated ncRNAs (pancRNAs) are associated with active chromatin marks, with the forced expression or knockdown of these pancRNAs causing DNA demethylation and methylation at the gene promoter, respectively.117,118

The association of Ago1, active RNAP, Dicer and promoter sense transcription with TGS suggests a rapid monitoring system for aberrant transcription such as might be expected by transcription from transposons, repeated sequences and proviruses, or from chromosome abnormalities.29,48,117–119

Presently, it is unknown why there is a distinct strand loading bias between Ago1 and Ago2. These argonautes are structurally very similar and it remains to be seen whether the loading bias is an intrinsic property of argonaute or of cofactors in a loading complex.

Disease Therapy

The demonstrated specificity and potentially long-term efficacy of exogenous sRNA in vitro, raises the potential for a new class of RNA-based drugs. It may be possible to develop cancer therapies or to stably suppress HIV-1 replication in the CD-4+ T cells of HIV patients. Indeed, many TGS and RNAAs studies target genes associated with cancer and the HIV-1 virus in cultured cells (Tables 1 and 2). To this end, the field has now matured to the point where in vivo experiments are being undertaken. The efficacy in vivo of sRNA-directed transcriptional silencing or activation to control tumor growth has been demonstrated using mouse xenograft models. In vivo, stable RNAAs activation of CCNB1 by miRNA constructs resulted in tumors with reduced size compared to controls.68 Similarly, treating established tumors with lipid transfections of siRNA targeting CDKN1A78 or CDH1 (ref. 77) every three days showed reduced tumor growth, relative to controls. In addition, dsRNA chemically modified for lipidoid-encapsulating nanoparticle delivery is efficacious in promoting RNAAs of CDKN1A in mouse xenografts.120,121

Effective lentiviral delivery of shRNA has also been demonstrated in vivo. The lentiviral transfer of VEGF promoter targeted shRNAs has been observed to increase blood flow in the hindlimbs of ischemic mice79 and recently, in this journal, Suzuki et al. showed that shRNA targeting the HIV-1 LTR was able to inhibit HIV-1 replication in lentiviral transduced human peripheral blood mononuclear cells circulating in humanized mice.122 These results show promise in the translation of exogenous sRNA therapy to the clinic. It is foreseeable that RNA-based drugs may eventually be used to reprioritize epigenetic state at a targeted locus.

Also, as we better understand endogenous nuclear sRNA processes, the mechanisms behind some diseases may be uncovered. In a now classic case, Tufarelli et al. documented a rare α-thalassaemia resulting from a deletion truncating LUC7L and bringing it, juxtaposed, within proximity of the HBA2 hemoglobin gene. Expression of the LUC7L antisense transcript resulted in epigenetic silencing of HBA2.123

Acknowledgments. The authors thank Peter Molloy (CSIRO) and Lloyd Graham (CSIRO) for their critical review of this manuscript. This work is supported by the CSIRO Preventative Health National Research Flagship. The authors declare no conflict of interest.

1. Meister, G (2013). Argonaute proteins: functional insights and emerging roles. Nat Rev Genet 14: 447–459.
2. Yigit, E, Battista, PJ, Bai, Y, Pang, KM, Chen, CC, Tolia, NH et al. (2008). Analysis of the C. elegans Argonaute family reveals that distinct Argonautes act sequentially during RNAi. Cell 127: 747–757.
3. Jerik, M and Doudna, JA (2009). A three-dimensional view of the molecular machinery of RNA interference. Nature 457: 405–412.
4. Bortvin, A (2013). PIWI-interacting RNAs (piRNAs) – a mouse testis perspective. Biochemistry Mosc 78: 592–602.
5. Liu, J, Carmell, MA, Rivas, FV, Marsden, CG, Thomson, JM, Song, JJ et al. (2004). Argonaute2 is the catalytic engine of mammalian RNAi. Science 305: 1437–1441.
6. Meister, G, Landthaler, M, Patkaniowska, A, Dorsett, Y, Teng, G and Tuschl, T (2004). Hlung Human Argonaute2 mediates RNA cleavage targeted by mRNAs and siRNAs. Mol Cell 15: 185–197.
7. Tam, OH, Aravin, AA, Stein, P, Giraud, A, Murchison, EP, Chelioufi, S et al. (2008). Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature 453: 534–538.
8. Carthew, RW and Sontheimer, EJ (2009). Origins and Mechanics of miRNAs and siRNAs. Cell 136: 642–655.
9. Babiarian, JE, Ruby, JG, Wang, Y, Bartel, DP and Bleloch, R (2008). Mouse ES cells express endogenous shRNAs, sRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. Genes Dev 22: 2773–2785.
10. Bartel, DP (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215–223.
11. Chelioufi, S, Dos Santos, CO, Chong, MM and Hanlon, GJ (2010). A Dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 465: 584–589.
12. Ciferrente, D, Xue, H, Taylor, DW, Patnode, H, Mishima, Y, Chelioufi, S et al. (2010). A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science 328: 1694–1698.
13. MacRae, IJ, Ma, E, Zhou, M, Robinson, CV and Doudna, JA (2008). A novel mechanism of human RISC-loading complex. Proc Natl Acad Sci USA 105: 512–517.
14. Liu, Y, Ye, X, Jiang, F, Liang, C, Chen, D, Peng, J et al. (2009). C3PO, an endonuclease that promotes RNAi by facilitating RISC activation. Science 325: 750–753.
15. Ye, X, Huang, N, Liu, Y, Parco, Z, Huerta, C, Li, P et al. (2011). Structure of C3PO and mechanism of human RISC activation. Nat Struct Mol Biol 18: 650–657.
16. Yamakawa, N, Okuyama, K, Ogata, J, Kanai, A, Helwak, A, Talamant, M et al. (2014). Novel functional small RNAs are selectively loaded onto mammalian Argonaute. Nucelic Acids Res 42: 5288–5301.
17. Van Struy, M, Ogün, TH 3rd, Chekhlov, S, Vogel, P, Watanabe, M, Pilili, MR et al (2012). Enhanced susceptibility of Ag0/13 double-null mice to influenza A virus infection. J Virol: 4151–4157.

18. Parisi, C, Giorgi, C, Batsata, EM, Braccini, L, Marasco, G, D’agronio, I et al (2011). Ag0 and Ag02 differentially affect cell proliferation, motility and apoptosis when overexpressed in SH-SY5Y neuroblastoma cells. FEBS Lett 585: 2965–2971.

19. Hu, Q, Tanasa, B, Tabatabi, M, Li, W, Zhang, Y, Ohgi, KA et al (2012). DICER- and AGO3-dependent generation of retinoic acid-indurged DR2 Alu RNAs regulate human stem cell proliferation. Nat Struct Mol Biol 19: 1168–1175.

20. Mozdzewski, AJ, Kaur, S, Hsu, SM, Gromin, A and Cohen, PE (2012). AGO3 regulates entry into meiosis and influences sex of chromosomeosomes in the male mouse germ line. Dev Cell 23: 251–264.

21. Wang, D, Zhang, Z, O’Loughlin, E, Lee, T, Houel, S, O’Carroll, D et al (2012). Quantitative functions of Argonaute proteins in mammalian development. Genes Dev 26: 695–704.

22. Polikepahad, S and Corgy, DB (2013). Profiling of T helper cell-derived small RNAs reveals unique antiviral transcripts, new miRNAs and different antiviral miRNAs. Nucleic Acids Res 41: 1194–1177.

23. Girnang, GS, John, A, Janow, S, Young, R, Deng, X, Pfeiler, GP et al (2013). Short hairpin-RNA induced transcriptional gene silencing in human cells. J Nucleic Acids Res 64: 906–910.

24. Campisi, S, Liu, J, Hu, J and Corey, D (2012). Expanding the action of duplex RNAs into the nucleus: a role for Argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding DNA sequence. Nucleic Acids Res 40: 552–559.

25. Han, J, Kim, D and Morris, K (2007). Promoter-bound small RNAs from promoter-proximal RNA polymerase II. Cell 130: 920–934.

26. Chu, Y, Yue, X, Young, SJ, Janowski, BA, Place, RF, Janowski, BA et al (2013). Ago2 facilitates Rad51-dependent generation of retinoic acid-induced DR2 Alu RNAs regulates human stem cell differentiation. J Biol Chem 288: 2965–2971.

27. Ghildiyal, M and Zamore, PD (2009). Small silencing RNAs: an expanding universe. Nat Rev Genet 10: 94–108.

28. Li, L, Chu, Y, Yue, X, Young, SJ, Janowski, BA, Place, RF et al (2014). Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells. Proc Natl Acad Sci USA 111: 16230–16235.

29. Hu, Q, Tanasa, B, Tabbah, M, Li, W, Zhang, Y, Ohgi, KA et al (2012). DICER- and AGO3-dependent generation of retinoic acid-indurged DR2 Alu RNAs regulate human stem cell proliferation. Nat Struct Mol Biol 19: 1168–1175.

30. Moschel, RA, Cooper, DA, Ishida, T, Watanebe, T, Cooper, D et al (2008). Nuclear Argonaute-Small RNA Complexes. J RNAi Gene Silencing 4: 532–541.

31. Ross and Kassir. (2009). Nucleic Acids Res 37: 1066–1075.

32. Castedonato, D, Tommassi, S, Li, M, Li, H, Yanov, S, Pfeifer, GP et al (2005). Short hairpin-RNA-directed cytospine (Cg/p) methylation of the RASSF1A gene promoter in HeLa cells. Mol Ther 12: 179–183.

33. Ahlenstiel, CL, Lim, HG, Cooper, DA, Ishida, T, Kelleher, AD and Suzuki, K (2012). Fluorescence correlation spectroscopy and fluorescence cross-correlation spectroscopy reveal the actin cytoskeleton to nuclear RNAi machinery in human cells. Nucleic Acids Res 40: 1240–1250.

34. Schwartz, JC, Younger, ST, Nguyen, NB, Hardy, DB, Monia, BP, Corey, D et al (2008). Regulation of endothelial nitric oxide synthase by small RNA. Proc Natl Acad Sci USA 105: 16967–16972.

35. Zhang, MX, Ou, H, Shen, HY, Wang, J, Wang, J, Coselli, J et al (2005). Regulation of germline. J Biol Chem 280: 259–266.

36. Weberg, MS, Vileneuve, LM, Ehsan, A, Amargougui, M, Aagaard, L, Chen, XZ et al (2006). The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA Biol 3: 693–704.

37. Turner, MP, Lehtola, T, Heinonen, SE, Asselt, GS, Kopsilas, P, Grimmy, R et al (2009). Effi1icient regulation of VEGF expression by promoter-targeted liver-specific shRNAs based on epigenetic mechanisms: a novel example of epigenetic therapy. Circ Res 105: 604–609.
73. Li, LC, Okino, ST, Zhao, H, Pookot, D, Place, RF, Urakami, S et al. (2006). Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA 103: 17337–17342.

74. Weinberg, MS, Barcichewy, S, Schaffer, L, Han, J and Morris, KV (2007). An RNA targeted to the HIV-1LTR promoter modulates indiscriminate off-target gene activation. Nucleic Acids Res 35: 7303–7312.

75. Janowaski, BA, Younger, ST, Hardy, DB, Ram, R, Huffman, KE and Corey, DR (2007). Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 3: 166–173.

76. Place, RF, Li, LC, Pookot, D, Noonan, EJ and Dahyia, R (2008). Antitumor effect of dsRNA-induced p21(WAF1/CIP1) gene activation in human bladder cancer cells. Mol Cancer Ther 7: 698–703.

77. Whitson, JM, Noonan, EJ, Pookot, D, Place, RF and Dahyia, R (2009). Double stranded-RNA-mediated activation of p21 gene induced apoptosis and cell cycle arrest in renal cell carcinoma. Int J Cancer 125: 466–472.

78. Yang, K, Zheng, XY, Qin, J, Wang, WB, Bai, Y, Mao, QG et al. (2008). Up-regulation of p21WAF1/Cip1 by siRNA induces G1-phase arrest and apoptosis in T24 human bladder cancer cells. Cancer Lett 252: 208–214.

79. Mao, Q, Li, YY, Zhang, X, Yang, K, Shen, H, Qin, J et al. (2008). Up-regulation of E-cadherin by small activating RNA inhibits cell invasion and migration in 5637 human bladder cancer cells. Biochem Biophys Res Commun 375: 566–570.

80. Mao, Q, Zheng, X, Yang, K, Qin J, Bai Y, Jia X et al. (2010). Suppression of migration and invasion of PC3 prostate cancer cell line via activating E-cadherin expression by small interfering RNA. Cancer Res 70: 10182–10191.

81. Wang, J, Place, RF, Huang, W, Wang, X, Noonan, EJ, Magyar, CE et al. (2010). Prognostic value and function of KLF4 in prostate cancer: RNAs and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res 70: 10182–10191.

82. Matsui, M, Sakurai, F, Elbashir, S, Foster, DJ, Manoharan, M and Corey, DR (2010). Activation of LDL receptor expression by small RNAs complementary to a noncoding RNA. Cancer Res 70: 10182–10191.

83. Wang, J, Place, RF, Huang, W, Wang, X, Place, RF, Lin, G et al. (2010). RNAi is conserved in mammalian cells. PLoS ONE 5: e8688.

84. Wang, X, Wang, J, Huang, V, Place, RF and Li, LC (2012). Induction of NANO3 expression by targeting promoter sequence with small activating RNA antagonizes retinoic acid-mediated activation of P21 gene expression in human cancer cells. Cancer Res 72: 430–441.

85. Wang, K, Shen, J, Xie, YQ, Lin, HW, Qin, J, Mao, QG et al. (2013). Promoter-targeted double-stranded small RNAs activate P21WAF1/CIP1 gene expression in human cancer cells. Int J Biochem Cell Biol 45: 1338–1346.

86. Matsu, M, Chu, Y, Zhang, H, Gagnon, KT, Shakh, S, Kuchinachin, S et al. (2013). Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res 41: 10086–10100.

87. Moses, J, Goodchild, A and Rivoy, LP (2010). Intended transcriptional silencing with siRNA results in gene repression through sequence-specific off-targeting. RNA 16: 430–441.

88. Ross, JP, Rand, KN and Molloy, PL (2010). Hypomethylation of repeated DNA sequences in cancer. Epigenomics 2: 245–269.

89. Karmodiya, K, Krebs, AR, Oulad-Abdelghani, M, Kimura, H and Tora, L (2012). H3K9 and H3K14 acetylation co-occur at many gene regulatory elements, while H3K14ac marks a widespread occurrence of antisense transcription in the human genome. Nat Biotechnol 30: 315–322.

90. Licatalosi, DD, Mele, A, Fak, JJ, Ule, J, Kayikci, M, Chi, SW et al. (2008). Up-regulation of endogenous RNAa is conserved in mice and a differentially expressed gene in hematopoietic stem cells. Genes Dev 22: 1025–1035.

91. Sladkova, Y, Yurkevich, N, Trach, M, Atanassova, V, Karpowicz, P and Yurchenko, VA (2008). Induction of NANOG expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 105: 1595–1599.

92. Yoon, JH, Abdelmohsen, K and Gorospe, M (2013). Posttranscriptional gene regulation by long noncoding RNA. J Mol Biol 425: 3723–3730.

93. Chiyomaru, T, Fusukawa, S, Saini, S, Majid, S, Deng, G, Shahnery, V et al. (2014). Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells. J Biol Chem 289: 12550–12561.

94. Li, CH, Tor, KF, Tong, JH, Xiao, Z, Tai, L, Bai, PB et al. (2013). Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology 144: 1086–1097.

95. Wang, J, Liu, X, Wu, H, Ni, G, Gu, Z, Qiao, Y et al. (2014). CREB up-regulates long non-coding RNA HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 42: 5368–5383.

96. Widelov, Dany, S, Reiker, LE, Vardeny, EO, Goldstein, O, Shoshan, A et al. (2003). Widespread occurrence of antisense transcription in the human genome. Nat Biotechnol 21: 379–386.

97. Meister, G and Tuschl, T (2004). Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.

98. Voos, JH, Abdelmohsen, K and Gorospe, M (2010). Double strand RNA-mediated activation of P21 gene induces apoptosis and cell cycle arrest in renal cell carcinoma. Int J Cancer 126: 466–472.

99. Zhuang, M, Gao, W, Xu, J, Wang, P and Shu, Y (2014). CREB up-regulates long non-coding RNA HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 42: 5368–5383.